文章基本信息

标题：Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk
本地全文：下载
作者：Sylvia Haas ; Christoph Bode ; Bo Norrving 等
期刊名称：Vascular Health and Risk Management
印刷版ISSN：1176-6344
电子版ISSN：1178-2048
出版年度：2014
卷号：10
页码：101-114
DOI：10.2147/VHRM.S55246
出版社：Dove Medical Press Ltd
摘要：Rivaroxaban is a direct factor Xa inhibitor that is widely available to reduce the risk of stroke or systemic embolism in patients with nonvalvular atrial fibrillation and one or more risk factors for stroke. Rivaroxaban provides practical advantages compared with warfarin and other vitamin K antagonists, including a rapid onset of action, few drug interactions, no dietary interactions, a predictable anticoagulant effect, and no requirement for routine coagulation monitoring. However, questions have emerged relating to the responsible use of rivaroxaban in day-to-day clinical practice, including patient selection, dosing, treatment of patients with renal impairment, conversion from use of vitamin K antagonists to rivaroxaban and vice versa, coagulation tests, and management of patients requiring invasive procedures or experiencing bleeding or an ischemic event. This article provides practical recommendations relating to the use of rivaroxaban in patients with nonvalvular atrial fibrillation, based on clinical trial evidence, relevant guidelines, prescribing information, and the authors' clinical experience.
关键词：novel oral anticoagulants; direct factor Xa inhibitor; peri-interventional management; practical guidance; rivaroxaban; stroke prevention